CY1113051T1 - Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α - Google Patents

Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α

Info

Publication number
CY1113051T1
CY1113051T1 CY20121100736T CY121100736T CY1113051T1 CY 1113051 T1 CY1113051 T1 CY 1113051T1 CY 20121100736 T CY20121100736 T CY 20121100736T CY 121100736 T CY121100736 T CY 121100736T CY 1113051 T1 CY1113051 T1 CY 1113051T1
Authority
CY
Cyprus
Prior art keywords
lactic
aids
deficiency
therapeutic treatment
preparations
Prior art date
Application number
CY20121100736T
Other languages
English (en)
Inventor
Richard Selden
Marianne Borowski
Carol M Kinoshita
Douglas A Treco
Melanie D Williams
Thomas J Schuetz
Peter Francis Daniel
Original Assignee
Shire Human Genetic Therapies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23012821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113051(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies, Inc. filed Critical Shire Human Genetic Therapies, Inc.
Publication of CY1113051T1 publication Critical patent/CY1113051T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)

Abstract

Η εφεύρεση προβλέπει εξαιρετικής καθαρότητας α-Gal Α και διάφορες μεθόδους για τον καθαρισμό αυτής· παρασκευάσματα α-Gal Α με αλλαγμένο φορτίο και μεθόδους για την κατασκευή αυτών των παρασκευασμάτων· σκευάσματα α-Gal Α με παρατεταμένη διάρκεια ημιζωής σε θηλαστικά ξενιστές και μεθόδους για την κατασκευή αυτών· καθώς και μεθόδους και δοσολογίες για τη χορήγηση παρασκευάσματος α-Gal Α σε κάποιο άτομο.
CY20121100736T 1999-03-11 2012-08-10 Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α CY1113051T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/266,014 US6458574B1 (en) 1996-09-12 1999-03-11 Treatment of a α-galactosidase a deficiency
EP10152432A EP2186902B1 (en) 1999-03-11 2000-03-09 Medical preparations for the treatment of alpha-galactosidase a deficiency

Publications (1)

Publication Number Publication Date
CY1113051T1 true CY1113051T1 (el) 2016-04-13

Family

ID=23012821

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20081100521T CY1107951T1 (el) 1999-03-11 2008-05-20 Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α
CY20121100736T CY1113051T1 (el) 1999-03-11 2012-08-10 Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α
CY20171100801T CY1119369T1 (el) 1999-03-11 2017-07-26 Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της αλφα-γαλακτοσιδασης α

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20081100521T CY1107951T1 (el) 1999-03-11 2008-05-20 Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20171100801T CY1119369T1 (el) 1999-03-11 2017-07-26 Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της αλφα-γαλακτοσιδασης α

Country Status (22)

Country Link
US (4) US6458574B1 (el)
EP (6) EP3231871A1 (el)
JP (6) JP2002538183A (el)
KR (2) KR100892334B1 (el)
CN (4) CN106110309A (el)
AT (1) ATE386808T1 (el)
AU (1) AU3519400A (el)
CA (3) CA3012663A1 (el)
CY (3) CY1107951T1 (el)
DE (1) DE60038104T2 (el)
DK (3) DK2314699T3 (el)
ES (3) ES2391221T3 (el)
HK (3) HK1043386B (el)
HU (1) HU228743B1 (el)
IL (2) IL145381A0 (el)
MX (1) MXPA01009222A (el)
NO (2) NO329689B1 (el)
NZ (1) NZ514077A (el)
PL (1) PL210833B1 (el)
PT (3) PT2314699T (el)
RU (1) RU2248213C2 (el)
WO (1) WO2000053730A2 (el)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
IL155588A0 (en) * 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) * 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
JP4641705B2 (ja) * 2001-04-30 2011-03-02 ザイストール セラピューティクス， インコーポレイテッド 治療的タンパク質の亜細胞標的化
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
EP2361631A1 (en) * 2002-04-25 2011-08-31 Shire Human Genetic Therapies, Inc. Treatment of alpha-galactosidase a deficiency
EP2857036B1 (en) 2003-01-31 2016-12-21 Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
US7422310B2 (en) * 2003-04-25 2008-09-09 Hewlett-Packard Development Company, L.P. Methods and apparatus for selecting image enhancement techniques
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
US20100196345A1 (en) * 2003-04-27 2010-08-05 Protalix Production of high mannose proteins in plant culture
US7442372B2 (en) † 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
JP4914224B2 (ja) 2004-02-10 2012-04-11 バイオマリン ファーマシューティカル インコーポレイテッド 酸性αグルコシダーゼおよびそのフラグメント
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
EP1773401B1 (en) * 2004-06-21 2013-01-02 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
CN1308444C (zh) * 2005-04-15 2007-04-04 中国人民解放军军事医学科学院野战输血研究所 基因重组α－半乳糖苷酶大批量发酵液的纯化方法
BRPI0612928A2 (pt) 2005-05-17 2010-12-07 Amicus Therapeutics Inc Método para aumentar a atividade de uma enzima de (alfa)-glucosidade em uma célula e método para tratar doença de pompe
ES2547726T3 (es) 2005-11-18 2015-10-08 Tokyo Metropolitan Institute Of Medical Science Nueva enzima altamente funcional que tiene especificidad de sustrato modificada
WO2007086067A1 (en) * 2006-01-30 2007-08-02 Diagnostic Technologies Ltd. Method for monitoring tocolytic treatment
CA2669347A1 (en) * 2006-11-13 2008-05-29 Zystor Therapeutics, Inc. Methods for treating pompe disease
AU2008246928B2 (en) * 2007-05-07 2014-04-17 Protalix Ltd. Large scale disposable bioreactor
WO2009032171A1 (en) * 2007-08-29 2009-03-12 Shire Human Genetic Therapies, Inc. Subcutaneous administration of alpha-galatosidase a
EP3778652A1 (en) * 2008-05-07 2021-02-17 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EP3075386B1 (en) 2009-06-17 2019-10-16 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
ES2606532T3 (es) * 2010-03-02 2017-03-24 Protalix Ltd. Alfa-galactosidasa estabilizada y usos de la misma
WO2011133802A1 (en) * 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
ES2761692T5 (es) * 2010-07-08 2023-07-05 Takeda Pharmaceuticals Co Método de producción de vWF recombinante de alto peso molecular en cultivo celular
ES2564358T3 (es) 2010-10-15 2016-03-22 The Trustees Of Columbia University In The City Of New York Genes relacionados con la obesidad y sus proteínas y usos de los mismos
DK2635299T3 (da) 2010-11-02 2019-10-21 Univ Columbia Fremgangsmåder til behandling af hårtabsforstyrrelser
WO2012121041A1 (ja) 2011-03-04 2012-09-13 株式会社糖鎖工学研究所 シアル酸含有糖鎖の製造方法
CN103906527B (zh) 2011-06-08 2020-07-10 川斯勒佰尔公司 Mrna递送的脂质纳米颗粒组合物和方法
KR20230066482A (ko) 2012-03-07 2023-05-15 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
SI2830662T1 (sl) 2012-03-29 2019-01-31 The Trustees Of Columbia University In The City Of New York Postopki zdravljenja motenj izgube las
EP2874648A4 (en) 2012-07-17 2015-12-30 Amicus Therapeutics Inc CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
WO2014016873A1 (en) 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
JP6226435B2 (ja) * 2012-07-26 2017-11-08 Ｊｃｒファーマ株式会社 組換えヒトα−ガラクトシダーゼＡの製造方法
WO2014120900A1 (en) * 2013-01-31 2014-08-07 Icahn School Of Medicine At Mount Sinai Enhanced therapeutic regimens for treating fabry disease
AU2014239264A1 (en) 2013-03-14 2015-08-27 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger RNA
CN105051213A (zh) 2013-03-14 2015-11-11 夏尔人类遗传性治疗公司 信使rna加帽效率的定量评估
TWI793159B (zh) 2013-10-23 2023-02-21 美商健臻公司 重組醣蛋白及其用途
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
WO2015134696A1 (en) 2014-03-05 2015-09-11 Ultragenyx Pharmaceutical Inc. Sialylated glycoprotein compositions and uses thereof
KR102455814B1 (ko) 2014-09-30 2022-10-18 아미쿠스 세라퓨틱스, 인코포레이티드 개선된 탄수화물을 가지는 고도로 강력한 산성 알파-글루코시다제
EP3237604A2 (en) * 2014-12-22 2017-11-01 Genzyme Corporation Methods of culturing a mammalian cell
PT3237621T (pt) 2014-12-22 2023-07-20 Codexis Inc Variantes da alfa-galactosidase humana
WO2016116966A1 (en) * 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
WO2017044807A2 (en) 2015-09-09 2017-03-16 The Trustees Of Columbia University In The City Of New York Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
MX2018008185A (es) 2015-12-30 2018-08-28 Amicus Therapeutics Inc Alfa-glucosidasa con mayor cantidad de acido para el tratamiento de la enfermedad de pompe.
JP2019508037A (ja) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ 標的化遺伝子編集を増強するための組成物およびその使用方法
WO2017173059A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
AU2017239641A1 (en) 2016-03-30 2018-10-18 Amicus Therapeutics, Inc. Formulations comprising recombinant acid alpha-glucosidase
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
CN110022904B (zh) * 2016-10-20 2024-04-19 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
JP2020503900A (ja) * 2017-01-10 2020-02-06 アミカス セラピューティックス インコーポレイテッド ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ
EA202290114A1 (ru) * 2017-03-30 2022-03-29 Амикус Терапьютикс, Инк. Способ отбора рекомбинантных белков с высоким содержанием m6p
WO2020047282A1 (en) * 2018-08-29 2020-03-05 University Of Copenhagen Lysosomal enzymes modified by cell based glycoengineering
BR112021011750A2 (pt) 2018-12-20 2021-08-31 Codexis, Inc. Alfa-galactosidase a recombinante e/ou fragmento de alfa-galactosidase a recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma variante de alfa-galactosidase a e para tratar e/ou prevenir os sintomas da doença de fabry, composição farmacêutica, e, uso das composições
WO2021005176A1 (en) 2019-07-09 2021-01-14 Genethon Treatment of glycogen storage disease (gsd)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5322158B2 (el) * 1974-05-02 1978-07-06
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
DE3580384D1 (de) 1984-04-09 1990-12-13 Toyo Boseki Praeparat mit verzoegerter freigabe zum aufbringen auf die schleimhaeute der mundhoehle.
US4764376A (en) 1984-06-18 1988-08-16 Eli Lilly And Company Method of inhibiting aromatase
GB8530631D0 (en) * 1985-12-12 1986-01-22 Ciba Geigy Ag Thrombin inhibitors
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5272066A (en) * 1986-03-07 1993-12-21 Massachusetts Institute Of Technology Synthetic method for enhancing glycoprotein stability
EP0463109A4 (en) 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5179023A (en) * 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
KR0159107B1 (ko) * 1989-07-13 1998-11-16 쟝 르쌍드뢰 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
JPH04502108A (ja) * 1989-09-05 1992-04-16 バイオテクノロジー　オーストラリア　ピーティーワイ　リミテッド 組替え生産物
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
US5661132A (en) * 1989-12-14 1997-08-26 Auragen, Inc. Wound healing
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5356804A (en) 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
ES2107537T3 (es) 1991-04-25 1997-12-01 Univ Brown Res Found Vehiculo inmunoaislante biocompatible implantable para suministrar productos terapeuticos seleccionados.
EP0592540B1 (en) 1991-07-02 2000-01-26 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5858751A (en) 1992-03-09 1999-01-12 The Regents Of The University Of California Compositions and methods for producing sialyltransferases
DE69312487T2 (de) 1992-05-18 1997-11-27 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
NZ257212A (en) 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
US5389539A (en) 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
EP0726964A4 (en) * 1993-09-23 1999-01-13 New England Biolabs Inc INSULATION AND COMPOSITION OF NEW GLYCOSIDASES
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5843015A (en) 1993-12-28 1998-12-01 Becton Dickinson And Company Molecules for iontophoretic delivery
US5789247A (en) 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
FR2718357B1 (fr) 1994-04-06 1997-10-03 Defarges Alain Moreau Perfectionnements apportés à un dispositif d'injection par jet sans aiguille.
US5834251A (en) * 1994-12-30 1998-11-10 Alko Group Ltd. Methods of modifying carbohydrate moieties
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
WO1996023869A1 (en) * 1995-01-30 1996-08-08 New York Blood Center, Inc. RECOMBINANT α-GALACTOSIDASE ENZYME
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US6566089B1 (en) * 1996-09-04 2003-05-20 Tularik Inc. Cell-based drug screens for regulators of gene expression
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
CN1268741C (zh) 1996-09-13 2006-08-09 超卡里奥迪克治疗学股份有限公司 半乳糖苷酶a缺乏症的治疗
IL125423A (en) * 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
US6749851B2 (en) * 2001-08-31 2004-06-15 Clearant, Inc. Methods for sterilizing preparations of digestive enzymes

Also Published As

Publication number Publication date
ATE386808T1 (de) 2008-03-15
CN101219213A (zh) 2008-07-16
HK1245320A1 (zh) 2018-08-24
JP2017014279A (ja) 2017-01-19
DE60038104D1 (de) 2008-04-03
JP2002538183A (ja) 2002-11-12
CN103585621A (zh) 2014-02-19
DE60038104T2 (de) 2009-02-12
ES2634317T3 (es) 2017-09-27
HK1043386A1 (en) 2002-09-13
EP2314699A1 (en) 2011-04-27
CA3012663A1 (en) 2000-09-14
JP6346236B2 (ja) 2018-06-20
CA2365923A1 (en) 2000-09-14
KR100892334B1 (ko) 2009-04-08
JP2011037867A (ja) 2011-02-24
PL210833B1 (pl) 2012-03-30
DK2186902T3 (da) 2012-09-03
NO329689B1 (no) 2010-11-29
PT2314699T (pt) 2017-08-01
NZ514077A (en) 2004-02-27
US20030077806A1 (en) 2003-04-24
US20030113894A1 (en) 2003-06-19
PT2186902E (pt) 2012-08-28
PT1163349E (pt) 2008-05-19
WO2000053730A2 (en) 2000-09-14
ES2300256T3 (es) 2008-06-16
PL350658A1 (en) 2003-01-27
MXPA01009222A (es) 2002-06-04
EP3231871A1 (en) 2017-10-18
CY1107951T1 (el) 2013-09-04
JP5899169B2 (ja) 2016-04-06
CN106110309A (zh) 2016-11-16
WO2000053730A3 (en) 2001-03-15
IL145381A0 (en) 2002-06-30
CA2833396C (en) 2018-08-28
JP5615648B2 (ja) 2014-10-29
KR20070090277A (ko) 2007-09-05
EP2186902B1 (en) 2012-05-23
NO20101493L (no) 2001-11-12
EP2186902A2 (en) 2010-05-19
CN103585621B (zh) 2016-08-10
EP2186902A3 (en) 2010-09-01
HUP0200467A2 (en) 2002-06-29
JP6081980B2 (ja) 2017-02-15
CN1354796A (zh) 2002-06-19
JP6626071B2 (ja) 2019-12-25
DK1163349T3 (da) 2008-06-23
ES2391221T3 (es) 2012-11-22
CA2833396A1 (en) 2000-09-14
JP2013241466A (ja) 2013-12-05
CY1119369T1 (el) 2018-02-14
HK1043386B (zh) 2008-06-13
US20110280856A1 (en) 2011-11-17
NO20014415L (no) 2001-11-12
RU2248213C2 (ru) 2005-03-20
EP1820862A3 (en) 2007-10-31
CN100417727C (zh) 2008-09-10
WO2000053730A9 (en) 2001-10-11
HK1143833A1 (en) 2011-01-14
EP2314699B1 (en) 2017-05-31
NO20014415D0 (no) 2001-09-11
EP1163349A2 (en) 2001-12-19
HUP0200467A3 (en) 2006-06-28
US6458574B1 (en) 2002-10-01
KR20020021371A (ko) 2002-03-20
JP2015091834A (ja) 2015-05-14
EP2287319A1 (en) 2011-02-23
KR100961740B1 (ko) 2010-06-07
HU228743B1 (en) 2013-05-28
JP2018038423A (ja) 2018-03-15
IL145381A (en) 2009-12-24
EP1820862A2 (en) 2007-08-22
AU3519400A (en) 2000-09-28
DK2314699T3 (en) 2017-08-07
EP1163349B1 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
CY1113051T1 (el) Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της α-γαλακτοσιδασης α
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
CY1112753T1 (el) Θεραπευτικη αγωγη καρκινων του ανθρωπινου σωματος με τη χρηση toy ετ743
MEP36608A (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
CY1110271T1 (el) Υδατικες παρατεταμενης-απελευθερωσης φαρμακοτεχνικες μορφες πρωτεϊνων
CY1108578T1 (el) Φαρμακευτικες συνθεσεις (κιτ) περιλαμβανοντας ενωσεις διϋδροπυριδινονης και εναν ανοσορυθμιστικο (ή εναν αντιφλεγμονωδη) παραγοντα και οι χρησεις αυτων
CY1109786T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματικων ασθενειων με την χρησιμοποιηση ενος διαλυτου μοριου ctla4
DK1641483T3 (da) Fusionsproteiner
CY1106283T1 (el) Κινολινυλ-πυρρολοπυραζολες
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
AR032293A1 (es) Estuche farmaceutico
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200000723A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
GEP20063799B (en) Tropane derivatives useful in therapy
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
ATE232396T1 (de) Oxydiertes thymosin beta 4
CY1106845T1 (el) Χρηση της φλουμαζενιλης για την παρασκευη ενος φαρμακου για την αγωγη της εξαρτησεως απο την κοκαϊνη
CY1107465T1 (el) Μελαγατρανη για τη θepαπευτικη αντιμετωπιση φλεγμονων
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1108871T1 (el) Υποκατεστημενα παραγωγα αμινο-φουραν-2-υλ-οξεικου οξεος και αμινο-θειεν-2-οξεικου οξεος και η χρησιμοποιηση τους για τη θεραπεια ημικρανιας ή πονου
DK1365808T3 (da) Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743